,5 PCa tumors start as AR dependent, but grow independent of testicular androgen, which prompted the development of the AR antagonist enzalutamide, an inhibitor of AR nuclear translocation,7 and abiraterone, which inhibits de novo androgen synthesis in tumors.8 The gene discussed is AR; the disease is posterior cortical atrophy.